ProKidney (PROK 515.00%) shares closed at $3.73, rising 515% today while the S&P 500 fell 0.1% and the Dow Jones Industrial Average dropped 0.4%.The chronic kidney disease-focused biotech experienced significant volatility, trading between $0.46 and $4.86 before settling near its upper range. The gain follows ProKidney's announcement of statistically and clinically meaningful topline results from its Phase 2 REGEN-007 clinical trial evaluating is autologous cell therapy treatment, called rilparencel, in pat ...